<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83993">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01926249</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2010/47</org_study_id>
    <nct_id>NCT01926249</nct_id>
  </id_info>
  <brief_title>A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders</brief_title>
  <acronym>MEMENTO</acronym>
  <official_title>A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Plan Alzheimer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter national prospective cohort study including at least 2300 individuals
      consecutively recruited from French Research Memory Centers and followed-up over 5 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The increasing incidence of Alzheimer's disease (AD) and related disorders with the change
      in the world age demographic is a source of major public health concern. Early and accurate
      identification of individuals at high risk of Alzheimer's Disease has become a priority.
      Over the last years, research has focused on the concept of &quot;Mild Cognitive Impairment&quot;
      which happens to be a heterogeneous condition as, depending on the studies, Mild Cognitive
      Impairment patients' conversion rates to dementia range from 2 to 15 percent per year. A
      study of the full range of stages of evolution, from preclinical stage, to clinical
      expression of dementia or death is therefore of utmost importance to improve our knowledge
      on AD and trigger the development of new treatments, especially if between stages transition
      can be related to neuroimaging (either structural or molecular), biological (Cerebro-Spinal
      Fluid, serum or plasma) or vascular damages markers. However, if all the above markers have
      been shown to be individually associated with worsening of cognitive status, no prior study
      has simultaneously explored the association of a large panel of risk factors and biomarkers
      with the progression through early signs of cognitive impairment until AD in a large sample
      of study participants. In parallel to improving the knowledge on AD, it is also important to
      better estimate the social and economic burden of AD and their consequences on the
      individuals and their circle and how they evolve from early phase (pre-clinical) of the
      disease to the most severe stages.

      This cohort, solution to the item 29 of the Plan Alzheimer 2008-2012, has been developed
      according to the initial memorandum of understanding prepared by the &quot;Comité Plan Cohortes&quot;
      of the Fondation Plan Alzheimer, and taking on board comments provided by the Scientific
      Advisory Board (July 2010) of the Fondation Plan Alzheimer and the whole working groups
      constituted for the preparation of the pilot phase: clinicians, neuro-imaging specialists,
      biologists, social sciences researchers (from June 2010). The cohort is built to fulfil the
      guiding principles as follows:

        -  It should be scientifically original and identify hypothesis-driven research, allowing
           a corpus of new or confirmatory knowledge of a high-level of evidence to be acquired.
           In addition, the infrastructure (standardised collection of socio-demographic,
           clinical, imaging, biological data) may allow to respond, in a timely manner, to
           additional questions that may emerge over time;

        -  An interdisciplinary approach is set up as the condition of individuals affected by
           neurodegenerative dementias involves clinical and biological aspects but also
           environmental, social and economic components;

        -  While pursuing its own original scientific objectives, the cohort should have the
           potential for a comparison with other equivalent cohorts around the world.

      This cohort will be including individuals at high risk of developing a neurodegenerative
      dementia. As such, the cohort is aiming at providing results with an expected impact for
      those individuals of the same profile, as well as their caregivers and their case
      management.

      One expected impact is to increase knowledge on the progression from early signs of
      cognitive impairment to AD and estimate associations between these signs and level of
      biomarkers assessed through imaging or blood or CSF samples. Another major expected impact
      is to standardise and harmonise protocols in terms of clinical and neuro-psychological
      examinations, biological markers, neuroimaging markers, diagnosis of dementia, support to
      caregivers and informants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Progression to clinical dementia stage according to standardized classifications (DSM-IV for dementia and NINCDS-ADRDA for Alzheimer's disease)</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of autonomy based on functional activity assessment</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Institutionalisation</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speed of cognitive decline based on change in cognitive performances</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular event (Stroke and Coronary events)</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prodromal AD (Pre-symptomatic dementia)</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal evolution of biomarkers measured from blood, Cerebro-Spinal Fluid (CSF), structural neuroimaging (MRI) and molecular neuroimaging (18F-FDG PET)</measure>
    <time_frame>Each 6 months from baseline for 5 years (M60)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Alzheimer's Disease (AD) and Related Disorders</condition>
  <arm_group>
    <arm_group_label>Individuals at high risk of developing Alzheimer's dementia</arm_group_label>
    <description>2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.
300 participants with an isolated cognitive complaint and an age of 60 years or more.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  Blood sampling

        -  Lumbar puncture (samples without DNA)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Outpatients from French Research Memory Centers with at least a light cognitive deficit
        defined as performing worse than one standard deviation to the mean in one or more
        cognitive domains or an isolated cognitive complaint regardless of its duration while
        being 60 years and older.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years and above

          -  Having at least a light cognitive deficit defined as performing worse than one
             standard deviation to the mean (compared to age and educational norms) in one or more
             cognitive domains (assessed from a neuropsychological tests battery exploring memory,
             language, praxis, vision, executive functions); this deviation being identified for
             the first time by tests performed less than 6 months preceding date of inclusion

          -  Or having isolated cognitive complaint regardless of its duration while being 60
             years and older

          -  Clinical Dementia Rating scale &lt;=0.5 and not demented

          -  Visual and auditory acuity adequate for neuropsychological testing

          -  Having signed an informed consent

          -  Being affiliated to health insurance

        Exclusion Criteria:

          -  Being under guardianship

          -  Residence in skilled nursing facility

          -  Pregnant or breast feeding women

          -  Alzheimer's disease caused by gene mutations

          -  Meeting brain MRI exclusion criteria (pacemakers, aneurysm clips, artificial heart
             valves, ear implants, metal fragments or foreign objects in the eyes, skin, or body)
             or refusing MRI

          -  Having a neurological disease such as: treated epilepsy, treated Parkinson's disease,
             Huntington disease, brain tumour, subdural haematoma, progressive supranuclear palsy,
             history of head trauma followed by persistent neurological deficits

          -  Stroke that has occurred in the last three months

          -  Schizophrenia history (DSM-IV criteria)

          -  Illiteracy, is unable to count or to read
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genevieve CHENE, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC-EC7 - ISPED - CHU de Bodeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève CHENE, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>CIC-EC7 - ISPED - CHU de Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carole DUFOUIL, Director</last_name>
    <role>Study Director</role>
    <affiliation>CIC-EC7 - ISPED</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geneviève CHENE, Prof.</last_name>
    <phone>(0)5 57 57 13 92</phone>
    <phone_ext>+33</phone_ext>
    <email>genevieve.chene@isped.u-bordeaux2.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carole DUFOUIL, Director</last_name>
    <phone>(0)5 57 57 14 23</phone>
    <phone_ext>+33</phone_ext>
    <email>carole.dufouil@isped.u-bordeaux2.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier GODEFROY, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Olivier GODEFROY, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BEAUCHET, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Olivier BEAUCHET, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre VANDEL, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Pierre VANDEL, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP - Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine BELIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine BELIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Xavier-Arnozan</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine HARSTON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sandrine HARSTON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François DARTIGUES, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François DARTIGUES, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle GENTRIC, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Armelle GENTRIC, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle JALENQUES, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle JALENQUES, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François SELLAL, MD</last_name>
    </contact>
    <investigator>
      <last_name>François SELLAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier ROUAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier ROUAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MOREAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier MOREAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence PASQUIER, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Florence PASQUIER, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre KROLAK-SALMON, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Pierre KROLAK-SALMON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu CECCALDI, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu CECCALDI, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey GABELLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Audrey GABELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanase BENETOS, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Athanase BENETOS, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine VERCELLETTO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martine VERCELLETTO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROBERT, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Philippe ROBERT, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital LARIBOISIERE</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques HUGON, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Jacques HUGON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hôpital BROCA</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier HANON, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Olivier HANON, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ap-Hp La Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno DUBOIS, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Bruno DUBOIS, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc PACCALIN, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Marc PACCALIN, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier HANNEQUIN, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Odile BARRELLON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Odile BARRELLON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric BLANC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric BLANC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie PARIENTE, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Jérémie PARIENTE, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno VELLAS, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Bruno VELLAS, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline HOMMET, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Caroline HOMMET, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>August 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
